Cargando…

Microbiome effects on immunity, health and disease in the lung

Chronic respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF), are among the leading causes of mortality and morbidity worldwide. In the past decade, the interest in the role of microbiome in maintaining lung health and in respiratory diseases...

Descripción completa

Detalles Bibliográficos
Autores principales: Shukla, Shakti D, Budden, Kurtis F, Neal, Rachael, Hansbro, Philip M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5382435/
https://www.ncbi.nlm.nih.gov/pubmed/28435675
http://dx.doi.org/10.1038/cti.2017.6
_version_ 1782520099537682432
author Shukla, Shakti D
Budden, Kurtis F
Neal, Rachael
Hansbro, Philip M
author_facet Shukla, Shakti D
Budden, Kurtis F
Neal, Rachael
Hansbro, Philip M
author_sort Shukla, Shakti D
collection PubMed
description Chronic respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF), are among the leading causes of mortality and morbidity worldwide. In the past decade, the interest in the role of microbiome in maintaining lung health and in respiratory diseases has grown exponentially. The advent of sophisticated multiomics techniques has enabled the identification and characterisation of microbiota and their roles in respiratory health and disease. Furthermore, associations between the microbiome of the lung and gut, as well as the immune cells and mediators that may link these two mucosal sites, appear to be important in the pathogenesis of lung conditions. Here we review the recent evidence of the role of normal gastrointestinal and respiratory microbiome in health and how dysbiosis affects chronic pulmonary diseases. The potential implications of host and environmental factors such as age, gender, diet and use of antibiotics on the composition and overall functionality of microbiome are also discussed. We summarise how microbiota may mediate the dynamic process of immune development and/or regulation focusing on recent data from both clinical human studies and translational animal studies. This furthers the understanding of the pathogenesis of chronic pulmonary diseases and may yield novel avenues for the utilisation of microbiota as potential therapeutic interventions.
format Online
Article
Text
id pubmed-5382435
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-53824352017-04-21 Microbiome effects on immunity, health and disease in the lung Shukla, Shakti D Budden, Kurtis F Neal, Rachael Hansbro, Philip M Clin Transl Immunology Review Chronic respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF), are among the leading causes of mortality and morbidity worldwide. In the past decade, the interest in the role of microbiome in maintaining lung health and in respiratory diseases has grown exponentially. The advent of sophisticated multiomics techniques has enabled the identification and characterisation of microbiota and their roles in respiratory health and disease. Furthermore, associations between the microbiome of the lung and gut, as well as the immune cells and mediators that may link these two mucosal sites, appear to be important in the pathogenesis of lung conditions. Here we review the recent evidence of the role of normal gastrointestinal and respiratory microbiome in health and how dysbiosis affects chronic pulmonary diseases. The potential implications of host and environmental factors such as age, gender, diet and use of antibiotics on the composition and overall functionality of microbiome are also discussed. We summarise how microbiota may mediate the dynamic process of immune development and/or regulation focusing on recent data from both clinical human studies and translational animal studies. This furthers the understanding of the pathogenesis of chronic pulmonary diseases and may yield novel avenues for the utilisation of microbiota as potential therapeutic interventions. Nature Publishing Group 2017-03-10 /pmc/articles/PMC5382435/ /pubmed/28435675 http://dx.doi.org/10.1038/cti.2017.6 Text en Copyright © 2017 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Review
Shukla, Shakti D
Budden, Kurtis F
Neal, Rachael
Hansbro, Philip M
Microbiome effects on immunity, health and disease in the lung
title Microbiome effects on immunity, health and disease in the lung
title_full Microbiome effects on immunity, health and disease in the lung
title_fullStr Microbiome effects on immunity, health and disease in the lung
title_full_unstemmed Microbiome effects on immunity, health and disease in the lung
title_short Microbiome effects on immunity, health and disease in the lung
title_sort microbiome effects on immunity, health and disease in the lung
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5382435/
https://www.ncbi.nlm.nih.gov/pubmed/28435675
http://dx.doi.org/10.1038/cti.2017.6
work_keys_str_mv AT shuklashaktid microbiomeeffectsonimmunityhealthanddiseaseinthelung
AT buddenkurtisf microbiomeeffectsonimmunityhealthanddiseaseinthelung
AT nealrachael microbiomeeffectsonimmunityhealthanddiseaseinthelung
AT hansbrophilipm microbiomeeffectsonimmunityhealthanddiseaseinthelung